Akèy › Leksemi mieloïd egi › Michigan › Ann Arbor
Etid klinik pou Leksemi mieloïd egi nan Ann Arbor, MI
17 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Ann Arbor (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi lwen
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi lwen
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Trinity Health Michigan Heart - Ann Arbor Campus, Ypsilanti · 7 mi lwen
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- ak 1 plis
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Ap rekriteFaz 1
- C S Mott Children's Hospital, Ann Arbor
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi lwen
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · 18 mi lwen
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · 15 mi lwen
- ak 1 plis
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- C S Mott Children's Hospital, Ann Arbor
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Ap rekriteFaz 3
- C S Mott Children's Hospital, Ann Arbor
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- C S Mott Children's Hospital, Ann Arbor
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- C.S. Mott Children's Hospital, Ann Arbor
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- University of Michigan, Ann Arbor
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- University of Michigan, Ann Arbor
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- University of Michigan, Ann Arbor
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Baldwin Park, CA40 etid
- Seattle, WA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA30 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Ann Arbor
- Kansè pwostat27 etid
- Kansè nan tete26 etid
- Kansè Poumon ki pa ti selil26 etid
- Kansè (tout kalite)25 etid
- Kansè kolorektal23 etid
- Kansè poumon23 etid
- Ensifizyans kadyak22 etid
- Maladi kadyovaskilè16 etid
- Kansè pankreyas14 etid
- Melanom12 etid
- Kansè renn (Kasinom selil renn)12 etid
- Karsinòm selil skuamèz tèt ak kou12 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.